Five-target Drug Beats Glp-1/gip Therapy In Obese Diabetic Mice

A targeted GLP-1–GIP–lanifibranor conjugate delivered wide metabolic benefits successful obese mice, pointing to a imaginable caller procreation of multi-pathway therapies for obesity and type 2 diabetes.

Study: GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and glucosuria successful mice. Image Credit: zimmytws / Shutterstock

A caller study published successful nan journal Nature describes nan creation of a caller single-molecule quintuple agonist designed to merge incretin-mediated metabolic regularisation pinch nan anti-inflammatory effects and insulin-sensitizing properties of lanifibranor.

In preclinical models, nan compound demonstrated greater efficacy than semaglutide and glucagon-like peptide-1 receptor (GLP-1R)–glucose-dependent insulinotropic polypeptide receptor (GIPR) dual therapy, resulting successful marked reductions successful assemblage weight, dietary intake, and humor glucose successful obese mice, while delivering nan supplier astatine a targeted debased dose.

The findings support targeted multi-pathway pharmacological strategies for communal cardiometabolic conditions specified arsenic glucosuria and obesity, but stay constricted to preclinical evidence.

Incretin and PPAR Agonist Therapy Background

The curen scenery for obesity and its metabolic complications has precocious quickly pinch incretin-based therapies and atomic receptor modulators. GLP-1R–GIPR co-agonists specified arsenic tirzepatide person shown beardown efficacy successful reducing assemblage weight, improving glycaemic control, and moreover benefiting liver outcomes successful metabolic dysfunction-associated steatohepatitis (MASH).

In parallel, peroxisome proliferator-activated receptor (PPAR) agonists, including nan triple PPARα/γ/δ compound lanifibranor, presently successful late-stage objective development, person attracted liking for their metabolic and anti-inflammatory effects. However, incretin therapies whitethorn not afloat resoluteness insulin guidance and inflammation, while PPAR agonists tin person adaptable information profiles, including weight changes and fluid imbalance, highlighting nan request for caller curen strategies.

Quintuple Agonist Study Design and Methods

To amended metabolic efficacy, this study developed and evaluated a single-molecule quintuple agonist that links incretin-based signaling pinch peroxisome proliferator-activated receptor (PPAR) activity. Lanifibranor, a triple PPAR agonist targeting α, γ, and δ subtypes, was chemically conjugated to a dipeptidyl peptidase-4 (DPP4)-protected incretin co-agonist backbone (MAR709). This creation enabled selective uptake successful cells expressing GLP-1 and GIP receptors.

The squad randomly assigned mice to curen groups, ensuring matching for genotype, age, assemblage mass, and wide assemblage composition. The animals received subcutaneous injections (5.0 μL/g) of vehicle, semaglutide, and GLP-1 mixed pinch lanifibranor, GIP, aliases both, astatine defined molar doses. In cardinal efficacy experiments, nan researchers treated diet-induced obese (DIO) mice for up to 12 days, including regimens of GLP-1–GIP–lanifibranor astatine doses of 5–50 nmol/kg.

The investigators assessed metabolic outcomes utilizing indirect calorimetry, assemblage creation analysis, and a scope of tolerance tests, including glucose, insulin, and pyruvate tolerance tests successful fasted mice. They besides performed hyperinsulinemia–euglycemic clamp studies and tissue-specific glucose uptake assays to quantify insulin sensitivity and glucose handling. They measured serum metabolites and hormones utilizing enzyme-linked immunosorbent assays (ELISA).

At nan molecular level, nan squad conducted bulk ribonucleic acerb sequencing (bulk RNA-seq) and analyzed differential cistron expression. They complemented these studies pinch in vitro experiments successful quality embryonic kidney 293T (HEK293T) cells, including bioluminescence resonance power transportation (BRET) assays and quantification of PPAR-responsive cistron activity. Proteomics, immunofluorescence, and conditioned sensation avoidance tests further characterized nan systemic and cellular effects of nan drug. All in vivo metabolic assessments were performed by blinded investigators.

Metabolic Effects of GLP-1–GIP–Lanifibranor

In vitro, nan GLP-1–GIP–lanifibranor conjugate showed comparable incretin receptor activity and akin glucose-induced insulin secretion arsenic its GLP-1R–GIPR dual receptor backbone. It besides induced look of PPAR-related target genes to a akin grade arsenic lanifibranor, but only successful cells expressing incretin receptors, confirming receptor-dependent activity. This targeted transportation strategy enabled pharmacological activity astatine lanifibranor exposures astir 6,900 times beneath a 30 mg/kg dose antecedently required to heighten liver metabolism successful preclinical settings.

In vivo, nan single-molecule conjugate showed superior efficacy compared pinch mixed GLP-1R and GIPR activation, semaglutide, and comparator regimens successful some diet-induced and familial obesity models, suggesting enhanced metabolic control. At 50 nmol/kg daily, GLP-1–GIP–lanifibranor produced placebo-corrected weight nonaccomplishment 2.63-fold greater than GLP-1–lanifibranor aft 14 days; consequent experiments identified 10 nmol/kg arsenic nan lead dose for further testing. These effects were accompanied by pronounced decreases successful fat mass, dietary intake, and humor glucose, on pinch improved oral glucose tolerance, enhanced insulin sensitivity, and stronger suppression of endogenous glucose production, apt driven by reduced hepatic gluconeogenesis and systemic inflammatory activity.

Mechanistically, nan curen improved insulin sensitivity and glucose uptake, peculiarly successful brownish adipose tissue, pinch glucose uptake akin to that of GLP-1–GIP successful respective different metabolic tissues, without expanding power expenditure aliases promoting adipocyte differentiation. Transcriptomic profiling identified much than 5,400 differentially expressed genes successful nan liver and complete 8,000 successful adipose tissue, indicating extended remodeling of inflammatory and metabolic pathways.

Genetic aliases pharmacological blockade of GIP, GLP-1, aliases PPARδ signaling markedly reduced metabolic effects, supporting a mixed incretin–PPAR system of action. Consistently, mice lacking some incretin receptors showed a complete nonaccomplishment of activity, confirming nan request for dual receptor engagement.

Preclinical Implications for Obesity and Diabetes

The study underscores nan committedness of combining incretin biology pinch atomic receptor signaling for much broad metabolic control. In preclinical models, nan GLP-1–GIP–lanifibranor conjugate improved weight, glycemia, and markers of glucose, liver, and cardiovascular usability successful mice while utilizing a lanifibranor-equivalent dose astir 6,900-fold little than a 30 mg/kg preclinical dose antecedently required to amended liver metabolism, suggesting improved dosing ratio and encouraging preclinical information signals. If translated to humans, specified multi-target strategies could amended reside nan increasing world load of obesity and type 2 diabetes, though objective validation, quality information testing, and mechanistic clarity stay essential.

New @Nature
A quintuple [GLP-1 + 4 other] receptor agonist supplier that exceeds effects of nan dual receptor (GLP-1 and GIP, tirzepatide) successful nan experimental exemplary vs glucosuria and obesity
(in lawsuit you thought a dual receptor was max effect, arsenic besides seen pinch retatrutide, a triple… pic.twitter.com/bvjCbj5Y6P

- Eric Topol (@EricTopol) April 29, 2026